All In Biotech

Drug Trial Radar · NCT05152368

Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells Exosomes for the Treatment of Trigeminal Neuralgia

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 9, 2022

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
The Foundation for Orthopaedics and Regenerative MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.

Conditions

  • Peripheral Neuropathy
  • Trigeminal Neuralgia

Interventions

  • cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomesBiological

    cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (adverse events)Time frame: Four year follow-up

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Prodromos Stem Cell Institute

    Naples, Florida · Recruiting

  • Prodromos Stem Cell Institute

    Athens, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.